Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592275 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT05592275 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 332 participants.
The verdict
NCT05592275, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Interventions
- DRUG Placebo
- DRUG LY3540378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05592275
The ClinicalTrials.gov registry entry for NCT05592275 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05592275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05592275 about?
NCT05592275 is a clinical study titled "A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)". The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
What is the current status of trial NCT05592275?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2023-02-03. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT05592275?
The interventions under investigation include: Placebo (DRUG), LY3540378 (DRUG).
Who is sponsoring clinical trial NCT05592275?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.